Aquestive Therapeutics (AQST) Asset Utilization Ratio (2018 - 2026)

Aquestive Therapeutics' Asset Utilization Ratio history runs 9 years deep, the most recent figure standing at 0.04 for Q1 2026.

• On a quarterly basis, Asset Utilization Ratio fell 91.7% year-over-year to 0.04 in Q1 2026; TTM through Mar 2026 was 0.04, a 91.7% decrease from a year earlier, with the FY2025 full-year figure at 0.01, down 99.01% from the prior year.
• Asset Utilization Ratio rose to 0.04 in Q1 2026 per AQST's latest filing, from 0.01 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.87 in Q4 2023 and bottomed at 0.01 in Q4 2025.
• The 5-year median for Asset Utilization Ratio is 0.55 (2024), against an average of 0.57.
• Across the five-year window, Asset Utilization Ratio soared 95.95% in 2022 and slumped 98.94% in 2025, its largest moves.
• Year by year, Asset Utilization Ratio stood at 0.78 in 2022, then grew by 11.14% to 0.87 in 2023, then plunged by 37.09% to 0.54 in 2024, then slumped by 98.94% to 0.01 in 2025, then surged by 663.3% to 0.04 in 2026.
• Per Business Quant, the three latest AQST Asset Utilization Ratio figures stand at 0.04 (Q1 2026), 0.01 (Q4 2025), and 0.34 (Q3 2025).